Could Astellas antibody be first-line treatment for gastric cancer?
Posted: 17 November 2022 | Catherine Eckford (European Pharmaceutical Review) | No comments yet
Monoclonal antibody Zolbetuximab plus mFOLFOX6 achieved significant progression-free survival in a Phase III trial for advanced gastric and gastroesophageal junction cancers.
Astellas Pharma Inc. announced patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, achieved significant progression-free survival (PFS) with Zolbetuximab, a first-in-class monoclonal antibody (mAb), in combination with mFOLFOX6 (oxaliplatin, leucovorin and fluorouracil) in a Phase III trial.
The SPOTLIGHT trial (NCT03504397) evaluated the efficacy and safety of Zolbetuximab, a chimeric IgG1 mAb, plus mFOLFOX6 compared to placebo with mFOLFOX6. Data showed statistical significance in PFS for the 566 participants with Claudin 18.2 (CLDN18.2)-positive, HER2-negative, locally advanced GEJ.
Zolbetuximab targets and binds to CLDN18.2, a transmembrane protein. CLDN18.2 is found in normal gastric cells and plays a major role in epithelial and endothelial tight junctions controlling the flow of molecules between cells.
In pre-clinical studies, this binding interaction caused cancer cell death by activating antibody-dependent cellular toxicity and complement-dependent cytotoxicity immune system pathways.
Based on the study data, around 38 percent of screened patients had CLDN18.2-positive tumours, defined as CLDN18.2 expression in ≥75 percent of tumour cells with strong-to-moderate staining intensity based on a validated immunohistochemistry assay.
The investigation met its secondary endpoint, overall survival (OS) with statistically significant results. Other secondary measures were objective response rate, duration of response, safety and tolerability and quality-of-life parameters.
The most frequent treatment-emergent adverse events (TEAEs) in patients treated with Zolbetuximab plus mFOLFOX6 were nausea, vomiting, and decreased appetite.
“I am excited by the potential for a new treatment option to help patients with advanced-stage gastric cancer or GEJ cancer,” shared Dr Kohei Shitara, primary investigator for the study and Chief, Department of Gastrointestinal Oncology at the National Cancer Center Hospital East in Kashiwa, Japan. “Gastric and GEJ cancers still have very limited treatment options available for patients with an advanced diagnosis.”
Dr Ahsan Arozullah, Senior Vice President and Head of Development Therapeutic Areas at Astellas stated, “We look forward to presenting the full results at a scientific congress in the near future.”
The SPOTLIGHT study and a Phase III GLOW trial, evaluating the efficacy and safety of Zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared to placebo plus CAPOX, are being conducted to obtain foundational data for regulatory submissions in regions such as US, Europe and Asia.